Institutional

The IRCM highlights Tarik Möröy's term as President and Scientific Director

Feb. 20 2019 | Appointment

All news

On March 1, 2006, Tarik Möröy became President and Scientific Director of the Montreal Clinical Research Institute (IRCM) and Director of the Hematopoiesis and Cancer Research Unit. The IRCM community paid tribute to him on February 19 to mark his thirteen years at the helm of the Institute.

After his successful terms as President and Scientific Director, Dr. Möröy will hand over this position to Max Fehlmann on March 1, 2019. However, Dr. Möröy remains at the IRCM as director of his research unit. 

“Throughout his terms of office, Dr. Möröy has achieved great accomplishments,” said Pierre Duplessis, Chair of the IRCM Board of Directors. “I sincerely thank him for his sustained commitment, through which the IRCM has not only maintained but strengthened its title as a leader in the scientific community in Quebec and Canada. As Chairman of the Board of Directors, I have been very pleased with our collaboration. I am delighted that this distinguished researcher will remain part of the Institute's wonderful community.”

Dr. Möröy is a Full Research Professor at Université de Montréal and an adjunct professor at McGill University. He holds the Canada Research Chair in Hematopoiesis and Immune Cell Differentiation. His research aims at advancing the understanding of the molecular basis of physiology, ontogenesis, and the differentiation of blood cells, and to reveal the mechanisms leading to cancer in the hematopoietic system, such as leukemia and lymphoma.  Dr. Möröy serves on the Board of Directors of Research Canada and is President of the Canadian Society for Molecular Biosciences.

In September 2018, Dr. Möröy was elected as a Fellow of the Canadian Academy of Health Sciences in recognition of his exemplary contributions in health sciences and the quality and innovation of his discoveries. He will receive the IRCM Merit Award during the IRCM Foundation’s next Annual Dinner, in recognition of his outstanding contribution to the growth of the Institute.

See the notice of appointment of Max Fehlmann